Denali Advisors’s Akero Therapeutics AKRO Stock Holding History

Denali Advisors’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-5,200	Closed	-$177K	–	418
2022 Q3	$177K	Buy	+5,200	New	+$79.6K	0.08%	142

Other funds holding AKRO

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Denali Advisors's AKRO Position: Q4 2022 in Review

Denali Advisors sold out of Akero Therapeutics (AKRO) in Q4 2022, closing a stake of 5,200 shares — an estimated $177K sold.

Denali Advisors first reported a position in AKRO in Q3 2022 and held it in 1 quarter. The position peaked at $177K in Q3 2022. 162 funds tracked by Wall St. Rank hold AKRO as of Q4 2022.

Denali Advisors reported no remaining Akero Therapeutics position as of Q4 2022 after selling out during the quarter.
Denali Advisors sold 5,200 Akero Therapeutics shares in Q4 2022, an estimated $177K.
Denali Advisors first reported a position in Akero Therapeutics in Q3 2022 and held it in 1 quarter.
Denali Advisors's Akero Therapeutics position peaked at $177K in Q3 2022.
162 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2022.

Based on Denali Advisors's 13F filing for Q4 2022, filed 9 Feb 2023.